Development of Conventional Multiplex PCR: A Rapid Technique for Simultaneous Detection of Soil-Transmitted Helminths.

Soil-transmitted helminths (STHs) are the most common intestinal parasites infecting humans worldwide. STH infections are a major cause of morbidity and disability. Accurate diagnostic tools are pivotal for assessing the exact prevalence of parasitic infections. Microscopic examination and culture techniques have been used to observe the presence of eggs or larvae of parasites in stool samples, but they are time-consuming and have low sensitivity. Therefore, accurate, simple, and inexpensive diagnostic techniques are still required for simultaneous detection of STH infections. Although molecular-based techniques, such as real-time PCR and multiplex real-time PCR, have been developed, they are not suitable for routine diagnosis due to the requirement for expensive reagents and instruments. In this study, we established a conventional multiplex PCR for simultaneous rapid detection of Ascaris lumbricoides, Necator americanus, and Strongyloides stercoralis in stool samples. Our results show that the multiplex PCR could detect the DNA of STHs at a very low target gene concentrations (lower than 1 pg) with no cross-amplification. Multiplex PCR had five times higher sensitivity than the formalin-ethyl acetate concentration technique (FECT) in the detection of multiple infections, and two times higher for detection of S. stercoralis. However, multiplex PCR was comparable to FECT in the detection of A. lumbricoides and N. americanus. In conclusion, this method could be used as an alternative method for the detection of STHs, especially for S. stercoralis.

Immunogenicity of a DNA and Recombinant Protein Vaccine Combining LipL32 and Loa22 for Leptospirosis Using Chitosan as a Delivery System.

Leptospirosis is a worldwide zoonotic disease caused by pathogenic Leptospira, a genus of which more than 250 serovars have been identified. Commercial bacterin vaccines are limited in that they lack both cross-protection against heterologous serovars and long-term protection. This study investigated in mice the immunogenicity of an anti-leptospirosis vaccine, using the outer membrane proteins LipL32 and Loa22 as antigens. The immunogenicity of this vaccine formulation was compared with those induced by vaccines based on LipL32 or Loa22 alone. A DNA-encapsulated chitosan nanoparticle was used for in vivo DNA delivery. Using a unique DNA plasmid expressing both lipL32 and loa22 for vaccination, higher antibody responses were induced than when combining plasmids harboring each gene separately. Therefore, this formulation was used to test the immunogenicity when administered by a heterologous prime (DNA)-boost (protein) immunization regimen. The specific antibody responses against LipL32 (total IgG and IgG1) and Loa22 (IgG1) were higher in mice receiving two antigens in combination than in those vaccinated with a single antigen alone. Although no significant difference in splenic CD4+ T cell proliferation was observed among all groups of vaccinated mice, splenocytes from mice vaccinated with two antigens exhibited higher interferon-γ and IL-2 production than when using single antigens alone upon in vitro restimulation. Taken together, the immunogenicity induced by LipL32 and Loa22 antigens in a heterologous primeboost immunization regimen using chitosan as a DNA delivery system induces higher immune response, and may be useful for developing a better vaccine for leptospirosis.

Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein.

Bacterial outer membrane lipoproteins represent potent immunogens for the design of recombinant subunit vaccines. However, recombinant lipoprotein production and purification could be a challenge notably in terms of expression yield, protein solubility, and post-translational acylation. Together with the cost effectiveness, facilitated production, and purification as well as good stability, DNA-based vaccines encoding lipoproteins could become an alternative strategy for antibacterial vaccinations. Although the immunogenicity and the efficacy of DNA-based vaccines can be demonstrated in small rodents, such vaccine candidates could request concrete optimization as they are weak immunogens in primates and humans and particularly when administered by conventional injection. Therefore, the goal of the present study was to optimize the immunogenicity of a DNA vaccine encoding an outer membrane lipoprotein. LipL32, the major outer membrane protein from pathogenic Leptospira, was selected as a model antigen. We evaluated the influence of antigen secretion, the in vivo DNA delivery by electroporation, the adjuvant co-administration, as well as the heterologous prime-boost regimen on the induction of anti-LipL32 specific immune responses. Our results clearly showed that, following transfections, a DNA construct based on the authentic full-length LipL32 gene (containing leader sequence and the N-terminus cysteine residue involved in the protein anchoring) drives antigen secretion with the same efficiency as a plasmid-encoding anchor-less LipL32 and for which the bacterial leader sequence was replaced with a viral signal peptide. The in vivo DNA delivery by electroporation drastically enhanced the production of strong Th1 responses characterized by specific IgG2a antibodies and the IFNγ secretion in a restimulation assay, regardless of the DNA constructs used. In comparison with the heterologous prime-boost regimen, the homologous prime-boost vaccinations with DNA co-administrated with polyinosinic-polycytidylic acid (poly I:C) generated the highest specific IgG and IgG2a titers as well as the greatest IFNγ production. Taken together, these data suggest that optimization of outer membrane lipoprotein secretion is not critical for the induction of antigen-specific responses through DNA vaccination. Moreover, the potent antibody response induced by DNA plasmid encoding lipoprotein formulated with poly I:C and delivered through electroporation provides the rationale for the design of new prophylactic vaccines against pathogenic bacteria.